Core Viewpoint - Dazhenglin Pharmaceutical Group Co., Ltd. will begin paying interest on its convertible bonds on October 22, 2025, for the period from October 22, 2024, to October 21, 2025 [2][13]. Summary by Sections Bond Issuance Details - The convertible bonds, named "Dazheng Convertible Bonds," were issued on October 22, 2020, with a total issuance amount of RMB 1,405 million [4]. - The bonds have a term of 6 years, maturing on October 21, 2026 [2][4]. - The face value of each bond is RMB 100 [2]. Interest Rate and Payment - The interest rates for the bonds are structured as follows: 0.30% for the first year, 0.60% for the second year, 1.00% for the third year, 1.50% for the fourth year, 1.80% for the fifth year, and 2.00% for the sixth year [2]. - For the fifth year, the interest rate is set at 1.80%, resulting in an interest payment of RMB 1.80 per bond (before tax) [13][17]. Payment Schedule - The bondholders will be registered on October 21, 2025, with the interest payment date also set for October 22, 2025 [4][19]. - The interest will be paid annually, and if the payment date falls on a holiday, it will be postponed to the next working day [6]. Conversion Terms - The conversion period for the bonds is from April 28, 2021, to October 21, 2026 [8]. - The initial conversion price is RMB 83.85 per share, while the latest conversion price is RMB 17.69 per share [10]. Tax Implications - Individual investors are subject to a 20% tax on interest income, resulting in a net payment of RMB 1.44 per bond after tax [17]. - Non-resident enterprises are exempt from corporate income tax on interest income until December 31, 2025 [18]. Credit Rating - The company and its convertible bonds have been rated "AA" with a stable outlook by China Chengxin International Credit Rating Co., Ltd. [10][11].